相似文献
1
Rare influenza A (H3N2) variants with reduced sensitivity to antiviral drugs.
Emerg Infect Dis. 2010 Mar;16(3):493-6. doi: 10.3201/eid1603.091321.
2
Amantadine resistance in relation to the evolution of influenza A(H3N2) viruses in Iran.
Antiviral Res. 2010 Nov;88(2):193-6. doi: 10.1016/j.antiviral.2010.08.013. Epub 2010 Sep 9.
3
Amantadine-resistant influenza A (H3N2) viruses in Iran.
Acta Virol. 2009;53(2):135-8. doi: 10.4149/av_2009_02_135.
4
Emergence and phylogenetic relationships of amantadine-resistant human H3N2 influenza A viruses in Germany in the season 2005/2006.
Int J Antimicrob Agents. 2008 Aug;32(2):192-5. doi: 10.1016/j.ijantimicag.2008.03.007. Epub 2008 Jun 20.
5
Zanamivir-resistant influenza viruses with Q136K or Q136R neuraminidase residue mutations can arise during MDCK cell culture creating challenges for antiviral susceptibility monitoring.
Euro Surveill. 2015;20(45). doi: 10.2807/1560-7917.ES.2015.20.45.30060.
6
7
High prevalence of amantadine-resistance influenza a (H3N2) in six prefectures, Japan, in the 2005-2006 season.
J Med Virol. 2007 Oct;79(10):1569-76. doi: 10.1002/jmv.20946.
8
[Evolution of influenza A(H3N2) virus from 2007 to 2012].
Vopr Virusol. 2013 Nov-Dec;58(6):27-31.
9
Epidemiology of human influenza A and B viruses in Myanmar from 2005 to 2007.
Intervirology. 2009;52(6):310-20. doi: 10.1159/000237738. Epub 2009 Sep 17.
10
Drug susceptibility of influenza A/H3N2 strains co-circulating during 2009 influenza pandemic: first report from Mumbai.
Infect Genet Evol. 2015 Jan;29:75-81. doi: 10.1016/j.meegid.2014.11.005. Epub 2014 Nov 11.
引用本文的文献
1
Whole-Genome Analysis of the Influenza A(H1N1)pdm09 Viruses Isolated from Influenza-like Illness Outpatients in Myanmar and Community-Acquired Oseltamivir-Resistant Strains Present from 2015 to 2019.
Viruses. 2024 Aug 15;16(8):1300. doi: 10.3390/v16081300.
2
New insights into the neuraminidase-mediated hemagglutination activity of influenza A(H3N2) viruses.
Antiviral Res. 2023 Oct;218:105719. doi: 10.1016/j.antiviral.2023.105719. Epub 2023 Sep 15.
3
Whole-Genome Analysis of Influenza A(H3N2) and B/Victoria Viruses Detected in Myanmar during the COVID-19 Pandemic in 2021.
Viruses. 2023 Feb 20;15(2):583. doi: 10.3390/v15020583.
4
Antivirals Targeting the Surface Glycoproteins of Influenza Virus: Mechanisms of Action and Resistance.
Viruses. 2021 Apr 6;13(4):624. doi: 10.3390/v13040624.
5
Phylogeographic analysis of human influenza A and B viruses in Myanmar, 2010-2015.
PLoS One. 2019 Jan 10;14(1):e0210550. doi: 10.1371/journal.pone.0210550. eCollection 2019.
6
and Characterization of Novel Neuraminidase Substitutions in Influenza A(H1N1)pdm09 Virus Identified Using Laninamivir-Mediated Selection.
J Virol. 2019 Mar 5;93(6). doi: 10.1128/JVI.01825-18. Print 2019 Mar 15.
7
Screening for Neuraminidase Inhibitor Resistance Markers among Avian Influenza Viruses of the N4, N5, N6, and N8 Neuraminidase Subtypes.
J Virol. 2017 Dec 14;92(1). doi: 10.1128/JVI.01580-17. Print 2018 Jan 1.
8
Influenza Virus: Small Molecule Therapeutics and Mechanisms of Antiviral Resistance.
Curr Med Chem. 2018;25(38):5115-5127. doi: 10.2174/0929867324666170920165926.
9
Drug resistance in influenza A virus: the epidemiology and management.
Infect Drug Resist. 2017 Apr 20;10:121-134. doi: 10.2147/IDR.S105473. eCollection 2017.
10
Peramivir: A Novel Intravenous Neuraminidase Inhibitor for Treatment of Acute Influenza Infections.
Front Microbiol. 2016 Mar 31;7:450. doi: 10.3389/fmicb.2016.00450. eCollection 2016.
本文引用的文献
1
Host cell selection of influenza neuraminidase variants: implications for drug resistance monitoring in A(H1N1) viruses.
Antiviral Res. 2010 Feb;85(2):381-8. doi: 10.1016/j.antiviral.2009.11.005. Epub 2009 Nov 13.
2
Rapid and specific detection of amantadine-resistant influenza A viruses with a Ser31Asn mutation by the cycling probe method.
J Clin Microbiol. 2010 Jan;48(1):57-63. doi: 10.1128/JCM.00698-09. Epub 2009 Nov 4.
3
Surveillance for neuraminidase-inhibitor-resistant influenza viruses in Japan, 1996-2007.
Antivir Ther. 2009;14(6):751-61. doi: 10.3851/IMP1194.
4
Epidemiology of human influenza A and B viruses in Myanmar from 2005 to 2007.
Intervirology. 2009;52(6):310-20. doi: 10.1159/000237738. Epub 2009 Sep 17.
5
Zanamivir-resistant influenza viruses with a novel neuraminidase mutation.
J Virol. 2009 Oct;83(20):10366-73. doi: 10.1128/JVI.01200-09. Epub 2009 Jul 29.
6
Emergence and spread of oseltamivir-resistant A(H1N1) influenza viruses in Oceania, South East Asia and South Africa.
Antiviral Res. 2009 Jul;83(1):90-3. doi: 10.1016/j.antiviral.2009.03.003. Epub 2009 Mar 24.
7
Oseltamivir-resistant influenza viruses A (H1N1), Norway, 2007-08.
Emerg Infect Dis. 2009 Feb;15(2):155-62. doi: 10.3201/eid1502.081031.
8
Surveillance for neuraminidase inhibitor resistance among human influenza A and B viruses circulating worldwide from 2004 to 2008.
Antimicrob Agents Chemother. 2008 Sep;52(9):3284-92. doi: 10.1128/AAC.00555-08. Epub 2008 Jul 14.
9
Amantadine-resistant influenza A (H3N2) virus in Japan, 2005-2006.
N Engl J Med. 2007 Jan 18;356(3):312-3. doi: 10.1056/NEJMc062989.
10
Increased adamantane resistance in influenza A(H3) viruses in Australia and neighbouring countries in 2005.
Antiviral Res. 2007 Feb;73(2):112-7. doi: 10.1016/j.antiviral.2006.08.002. Epub 2006 Aug 28.
Zotero 插件
